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http://dx.doi.org/10.1016/j.ccr.2013.04.026SUMMARYBreast cancer is a heterogeneous disease and can be classified based on gene expression profiles that
reflect distinct epithelial subtypes.We identify prostate-derived ETS factor (PDEF) as amediator ofmammary
luminal epithelial lineage-specific gene expression and as a factor required for tumorigenesis in a subset of
breast cancers. PDEF levels strongly correlate with estrogen receptor (ER)-positive luminal breast cancer,
and PDEF transcription is inversely regulated by ER and GATA3. Furthermore, PDEF is essential for luminal
breast cancer cell survival and is required in models of endocrine resistance. These results offer insights into
the function of this ETS factor that are clinically relevant and may be of therapeutic value for patients with
breast cancer treated with endocrine therapy.INTRODUCTION
Human breast cancer can be clustered into subtypes including
basal, luminal, and ERBB2+ tumors (among others) based on
gene expression profiling (Sørlie et al., 2001). Basal-like breast
cancer is characterized by the absence of estrogen receptor
(ER), progesterone receptor (PR), and ERBB2/HER2 and is
commonly more aggressive and invasive, whereas luminal
breast cancer is typically ER+ and is generally associated with
a better prognosis. ER regulates gene expression in cooperation
with coactivator or corepressor proteins and drives breast
cancer cell survival and growth. This dependence is the basis
for the treatment of ER+ luminal tumors with endocrine therapies
including aromatase inhibitors that reduce estrogen levels and
direct ER antagonists such as tamoxifen and fulvestrant
(Osborne and Schiff, 2011). However, the long-term efficacy ofSignificance
ER is the defining transcription factor of luminal breast tumor
standards of care in breast cancer. However, intrinsic and acqu
highlighting the need to identify additional pathways critical fo
evidence that prostate-derived ETS factor (PDEF) can drive
regulate the survival of luminal tumor cells, and contribute to e
PDEF expression may play a role in tumor recurrence followin
the treatment of patients with luminal breast cancer.these treatments is diminished by recurrence of resistant tumors
that have lost dependence on estrogen for growth. Although
some of the mechanisms underlying this acquired resistance
have been identified, including altered ER regulation and
increased HER2 activity, identification of other pathways is
essential to inform the design of additional therapies for these
patients.
The gene expression differences between basal and luminal
breast cancers represent distinctions in the expression of
lineage markers identified in the two types of normal mammary
epithelial cells: basal myoepithelial cells surrounding the
branching ductal structures, and ductal luminal epithelial cells
that generate milk-producing alveolar cells during pregnancy.
These cells arise from a common multipotent stem/progenitor
cell through a process of lineage commitment (Stingl et al.,
2005). Altered regulation of developmental pathways has beens, and endocrine agents that target ER are well-established
ired resistance limit the success of this therapeutic strategy,
r luminal tumor growth and recurrence. Our findings provide
luminal differentiation of basal mammary epithelial cells,
ndocrine resistance. These findings suggest that increased
g endocrine therapy and may be a clinically useful target for
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Figure 1. PDEF Induces a Luminal Lineage-Specific Gene Expression Profile in Non-Transformed Mammary Epithelial Cells
(A) Heatmap generated frommicroarray analysis of triplicate samples ofMCF-10A cells expressing either vector control (pBabe) or PDEF. Differentially expressed
mammary epithelial marker genes are shown. These expression changes were statistically significant (p = 4.14 3 1014 by Fisher’s exact test).
(B) Western blot analysis of vector control or PDEF-expressing MCF-10A cells (*NS band).
(C) Immunofluorescent staining for keratins 8 and 14 inMCF-10A cells. Representative images of vector control and PDEF-expressing cells are shown. Scale bars
represent 100 mM. Quantitation is shown in graph. Data represent mean ± SEM (***p < 0.0007).
(D) Western blot confirming PDEF overexpression in HMECs.
(E) Real-time PCR analysis of luminal (left) and basal (right) marker gene expression in HMECs overexpressing PDEF. Results were normalized to the
housekeeping gene RPLP0 and are presented as mean fold change ± SD (*p < 0.05, **p < 0.008).
(legend continued on next page)
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PDEF Is a Lineage-Specific Cancer Geneproposed to play an important role in tumorigenesis and to
contribute to the observed heterogeneity in breast cancer (Dontu
et al., 2003). Identification of other factors that regulate mam-
mary gland differentiation is important for understanding the
mechanisms of breast cancer initiation and progression and for
developing targeted treatments for each tumor subtype. Several
transcription factors involved in both mammary development
and breast cancer progression have been identified, including
GATA3, which promotes luminal epithelial differentiation and
exerts a tumor-suppressive function by sustaining differentiation
and inhibiting metastasis (Asselin-Labat et al., 2007; Kouros-
Mehr et al., 2008).
Members of the ETS family, such as ELF3, ELF5, and ETV4,
have also been implicated in mammary development (Shepherd
and Hassell, 2001) and are overexpressed in breast cancer,
supporting a role in epithelial tumorigenesis (Galang et al.,
2004; Kalyuga et al., 2012). Unlike most ETS proteins, the
expression of prostate-derived ETS factor (PDEF/SPDEF), which
was first identified as an activator of prostate specific antigen,
(Oettgen et al., 2000) is largely restricted to epithelial tissues
including the lung, stomach, colon, and hormone-regulated
epithelia such as the prostate, breast, and ovary. In these
tissues, PDEF mediates epithelial cell fate decisions and secre-
tory cell differentiation (Gregorieff et al., 2009; Park et al.,
2007); however, it is unclear whether PDEF functions similarly
in the mammary gland. There is also little known about the regu-
lation of PDEF expression apart frommiRNA-mediated suppres-
sion in basal breast cancer cell lines (Findlay et al., 2008).
PDEF also appears to play a role in regulating tumor growth
and loss of PDEF is associated with a more aggressive pheno-
type in prostate and colon cancer (Gu et al., 2007; Moussa
et al., 2009). However, the role of PDEF in breast cancer is
controversial, as several studies have demonstrated that
PDEF expression is lost in invasive basal breast cancer cell
lines, and that its re-expression inhibits the growth and migra-
tion of these cells, supporting a tumor-suppressive function
(Feldman et al., 2003; Turner et al., 2007). In contrast, PDEF
cooperates with known oncogenes to stimulate MCF-10A cell
transformation (Gunawardane et al., 2005) and is one of the
most highly overexpressed genes in human and mouse mam-
mary tumors and in lymph node metastases (Galang et al.,
2004; Ghadersohi and Sood, 2001). Furthermore, PDEF expres-
sion is enriched in luminal tumors and correlates with poor over-
all survival in ER+ breast cancer patients, suggesting instead a(F) Flow cytometry surface marker analysis of HMECs using antibodies for th
experiment is shown; similar results were obtained in two independent experime
(G) PDEF overexpression in COMMA-1D murine mammary epithelial cells was de
PCR (bottom); two independent shRNAs (PDEF KD: KnockDown #1 and #2) wer
housekeeping gene RPLP0 and are presented as mean fold change ± SEM (*p <
(H) COMMA-1D cells infected with lentivirus to modulate PDEF expression were p
Colonies were scored based on K8 (red) and K14 (green) staining and categorized
colonies. Representative images of each type of colony are shown (left), scale bars
and PDEF-downregulated cells (right, ± SD) are shown as the average fold change
cells (*p < 0.05, **p < 0.006, ***p < 0.0001).
(I) Box plot displaying PDEFmRNA levels in MaSC, luminal progenitors, mature lu
human mammary epithelial subpopulations (Lim et al., 2009).
(J) RelativemRNA expression levels of luminal (left) andmyoepithelial (right) marke
shRNA. Cells were harvested 5 days after infection. Bars represent fold change
See also Figure S1 and Table S1.possible oncogenic role (Sood et al., 2007, 2009; Gunawardane
et al., 2005).
In this study we sought to investigate and clarify the role of
PDEF in both normal mammary gland development and breast
cancer. We hypothesize that PDEF may be important for the
differentiation of normal mammary luminal cells and that this
transcription factor may function differentially in luminal versus
basal breast tumors.
RESULTS
PDEF Induces a Luminal Epithelial Gene Expression
Program in Mammary Epithelial Cells
To investigate PDEF function in the mammary gland, we exam-
ined the effect of this transcription factor on gene expression
using microarray-based profiling of MCF-10A cells. These cells
are nontransformed mammary epithelial cells that express pro-
tein and gene expression programs of basal epithelial cells
(Neve et al., 2006) and undetectable levels of endogenous
PDEF (Gunawardane et al., 2005). Bioinformatics analysis of
the genes induced or repressed by PDEF overexpression in
MCF-10A cells revealed a striking effect on expression of luminal
andmyoepithelial cell markers. The heat map in Figure 1A shows
the effects of PDEF overexpression on genes previously identi-
fied to be most specifically expressed in purified populations
of primary luminal (left column, yellow) or myoepithelial cells
(left column, blue) (Allinen et al., 2004; Jones et al., 2004).
PDEF overexpression induced a switch in gene expression,
resulting in the induction of luminal markers such as ERBB3,
MUC1, and AZGP1 and the concomitant suppression of
myoepithelial marker genes, including KRT14, CAV1, and
DCN. A complete list of the significantly regulated genes from
the microarray is shown in Table S1 (available online).
These results were validated in MCF-10A cells at the mRNA
level using quantitative real-time PCR (Figures S1A and S1B)
and at the protein level by western blot (Figure 1B). Expression
of PDEF also resulted in a shift to a luminal, EpCAM+CD10
phenotype (76.5% versus 45.9% in vector control cells) as deter-
mined by flow cytometry surface marker analysis (Figure S1C),
as well as a significant increase in luminal keratin-8+ (K8) cells
with a simultaneous decrease in the percentage of myoepithelial
keratin-14+ (K14) cells (Figure 1C). In addition, PDEF expression
in a second, independent cell line, non-transformed human
mammary epithelial cells (HMECs) (Figure 1D), also resulted ine luminal gene EpCAM and the myoepithelial gene CD10. A representative
nts.
tected by western blot (top). PDEF downregulation was detected by real-time
e used and compared to a NS shRNA control. Results were normalized to the
0.02, ***p < 0.0005).
lated on a layer of irradiated fibroblast feeder cells for colony formation assays.
into three types of colonies: K8+ luminal, K14+myoepithelial, or K8+K14+mixed
represent 100 mM.Quantitation of PDEF-overexpressing cells (middle, ± SEM)
in colony number across three experiments compared to vector or NS control
minal cells, and stromal cells derived from gene expression analysis of purified
rs in luminal progenitor cells transducedwith PDEF-targeting shRNA (KD) or NS
± SD of two independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001).
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PDEF Is a Lineage-Specific Cancer Geneinduction of luminal gene expression and inhibition of myoepi-
thelial marker genes (Figure 1E) and a shift to a luminal, EpCAM+
CD10 phenotype (83.4% versus 4.71% in vector control cells)
(Figure 1F).
To further validate the possibility that PDEF regulates luminal
differentiation, we examined the effect of modulating PDEF
expression in a murine mammary epithelial cell line, COMMA-
1D cells. These cells are derived from a mid-pregnant mouse
and contain a population of stem/progenitor cells that are
capable of both in vitro differentiation andmammary gland repo-
pulation in transplantation assays (Danielson et al., 1984).
Endogenous PDEF levels in these cells are low but can be
detected using real-time PCR (Figure 1G). COMMA-1D cells
were infected with lentiviral vectors expressing either PDEF
cDNA or shRNAs targeting PDEF and then assayed for colony
formation and scored for K8 and K14 staining (Figure 1H, left).
PDEF mRNA was efficiently downregulated with each of two in-
dependent shRNAs (PDEF KnockDown #1 and #2) compared to
a nonspecific (NS) shRNA control. Similar to the effects of PDEF
on keratin expression in MCF-10A cells, PDEF overexpression in
COMMA-1D cells led to enhanced formation of K8+ luminal
colonies and a reduction in K14+ colonies (Figure 1H, middle).
In contrast, downregulation of PDEF expression decreased the
formation of K8+ luminal colonies and resulted in an increased
proportion of K8+K14+ mixed colonies (Figure 1H, right), sug-
gesting a block in luminal differentiation and the accumulation
of bipotent double-positive colonies in the absence of PDEF.
In addition, gene expression analysis of FACS-sorted primary
human breast epithelial subpopulations (Lim et al., 2009)
revealed that PDEF mRNA levels are enriched in the CD49f+
EpCAM+ luminal progenitor cell population and are further
enriched in CD49f-EpCAM+ mature luminal cells, as compared
to the basal/mammary stem cell-enriched (Basal/MaSC) and
stromal fibroblast populations (Figure 1I). To determine whether
PDEF regulates the expression of luminal and myoepithelial
differentiation markers, we used this same FACS-sorting
approach to purify mammary epithelial subpopulations from a
reduction mastectomy specimen (Figures S1D and S1E).
Although sorted mature luminal cells could not be cultured, we
were able to successfully grow luminal progenitor cells in vitro
and evaluated the expression of several luminal and myoepi-
thelial markers after PDEF silencing in these cells (Figure 1J).
Interestingly, PDEF knockdown significantly decreased the
expression of multiple luminal markers, whereas myoepithelial
marker expression was not significantly affected. These results
further support a role for PDEF in driving the expression of
luminal-specific genes and promoting the differentiation of this
subset of mammary epithelial cells.
PDEF Is Co-Expressed with ER and Is Regulated by
ER-Cooperating Factors GATA3 and FOXA1
PDEF mRNA is significantly overexpressed in ERBB2+ and
luminal A and B tumors in two independent data sets, as
compared to basal-like tumors (Figure 2A). This correlation
with the luminal subtype was also confirmed in breast cancer
cell lines (Figure 2B). Because ER expression is themajor molec-
ular determinant of luminal tumors (Perou et al., 2000), PDEF is
significantly overexpressed in ER+ tumors (Figure 2C). Interest-
ingly, PDEF is the only ETS transcription factor displaying a756 Cancer Cell 23, 753–767, June 10, 2013 ª2013 Elsevier Inc.positive correlation with ER expression among the 28 members
of the family (Figure 2D). This correlation suggests that ER may
regulate PDEF transcription.
To determine if ER regulates PDEF expression, we analyzed a
previously established ER cistrome data set (Carroll et al., 2006)
and found three ER-binding regions located in the PDEF gene
locus (Figure 3A). Two enhancers (1 and 2) are located within
the first intron of the gene and the third one (3) is located after
the 30-end of the gene. Direct ER chromatin immunoprecipitation
(ChIP) in MCF7 cells showed an estradiol (E2)-induced recruit-
ment of ER at these three enhancers, thus confirming PDEF as
a direct ER target.
However, a time course analysis of MCF7 cells treated with
increasing E2 doses did not reveal PDEF mRNA induction, in
contrast with the strong increase of PR mRNA, a known direct
ER target (Figure 3B). Direct RNA polymerase II (Pol2) ChIP
corroborated the absence of PDEF induction by E2. Pol2
recruitment at the PDEF promoter was not increased after E2
treatment, whereas its recruitment at the PR promoter was
strongly induced (Figure 3C). We investigated whether the three
enhancers could be responsible for the activation of the genes
adjacent to PDEF (PACSIN1 and c6orf106, Figure S2A). How-
ever, neither of these neighboring genes demonstrated a corre-
lation with ER expression in breast carcinomas (Figure S2B), and
E2 stimulation did not induce their expression (Figure S2C). The
absence of PDEFmRNA induction by E2 was further validated in
another ER+ breast cancer cell line (T47D, Figure S2D). In addi-
tion, ER downregulation in MCF7 cells did not affect PDEF
mRNA levels (Figure 3D), further confirming the absence of reg-
ulatory activity, despite direct ER recruitment at the PDEF gene
locus in an E2-dependent manner.
These results suggested that a potential repressor prevents
transactivation of the PDEF gene by ER. Therefore, we examined
the roles of the known ER-cooperating factors FOXA1 (Lupien
et al., 2008) and GATA3 (Theodorou et al., 2013) as potential reg-
ulators of PDEF expression. FOXA1 downregulation in MCF7
cells led to a decrease in PDEF mRNA and protein levels, indi-
cating a positive role of FOXA1 in the regulation of PDEF expres-
sion (Figure 3D). FOXA1 downregulation in another luminal cell
line (SKBR3) also decreased PDEF mRNA levels (Figure S2E).
In contrast, GATA3 downregulation in MCF7 cells triggered an
increase of PDEF mRNA and protein levels (Figure 3D), demon-
strating a negative role of GATA3 in the regulation of PDEF
expression. Additionally, GATA3 overexpression in two luminal
cell lines expressing low endogenous GATA3 levels resulted in
decreased PDEF expression (Figure S2F). These regulatory
effects occur through direct recruitment of FOXA1 and GATA3
at the PDEF locus in MCF7 cells because direct ChIP-qPCR
revealed FOXA1 recruitment at the PDEF promoter and
enhancer 3, whereas GATA3 was recruited at the most proximal
enhancer (Figure 3E). These data suggest that PDEF is a down-
stream target of ER, FOXA1, and GATA3. As a control, we
verified that PDEF downregulation did not affect the expression
of ER, FOXA1, or GATA3, indicating that there is no reciprocal
regulatory loop between these genes (Figure S2G).
GATA3 Prevents ER-Mediated Induction of PDEF
As a direct PDEF repressor, GATA3 could be responsible for the
absence of E2-mediated induction of PDEF mRNA. To test this
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Figure 2. PDEF Is Enriched in Luminal Tumors and Strongly Correlates with ER Expression
(A and B) Box plots displaying PDEFmRNA levels between Basal-like, ERBB2+, and Luminal (Lum) subtypes of breast cancer (A) and breast cancer cell lines (B)
using published microarray data sets (Lu et al., 2008; Perou et al., 2000; Neve et al., 2006).
(C) Box plots displaying PDEF mRNA levels between ER- and ER+ breast carcinoma (F.C., fold change) in published microarray data sets (Chin et al., 2006;
Richardson et al., 2006; Wang et al., 2005).
(D) Heatmap displaying the relative expression levels of the 28 ETS transcription factors in ER and ER+ breast cancer subtypes (Wang et al., 2005; Richardson
et al., 2006; Chin et al., 2006) (N.D., not determined).
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PDEF Is a Lineage-Specific Cancer Genehypothesis, we compared the effect of E2 treatment in the pres-
ence or absence of GATA3 expression (Figure 4A). As expected,
PDEF mRNA levels were unchanged in MCF7 cells transfected
with a non-specific siRNA (NS). In contrast, GATA3 knockdown
enabled the induction of PDEF mRNA (Figure 4A) and protein
(Figure 4B) by E2 treatment. We then examined whether modu-
lation of GATA3 expression affected the recruitment of various
transcriptional regulators to the PDEF promoter and enhancer
regions using ChIP in E2-treated MCF7 cells (Figure 4C). Indeed,
Pol2 displayed a higher recruitment level at thePDEF promoter in
GATA3-knockdown conditions, whereas the promoter of the ERtarget gene MYC did not show differential Pol2 recruitment. ER
recruitment to the three enhancers was also increased upon
GATA3 depletion, with a more pronounced increase at enhancer
1, in contrast to the ER-recruiting enhancer located upstream of
theMYC gene, which did not show differential ER recruitment. In
the absence of estrogen stimulation (vehicle condition), ER
recruitment at the PDEF enhancers was close to background
level, and modulation of GATA3 expression did not affect ER
recruitment (Figure S3). Furthermore, the transcriptional coacti-
vator p300, known to associate with ligand-bound ER and to
augment ligand-dependent activation by ER (Hanstein et al.,Cancer Cell 23, 753–767, June 10, 2013 ª2013 Elsevier Inc. 757
Figure 3. PDEF Is Not Directly Regulated by ER, but Is Activated by FOXA1 and Repressed by GATA3
(A) Left: Schematic diagram of the ER-binding regions within the PDEF gene locus as defined by ER ChIP on chip in MCF7 cells (Carroll et al., 2006). Enh.,
enhancer. Right: direct ER chromatin immunoprecipitation (ChIP) followed by qPCR after treatment of MCF7 cells with vehicle (black bars) or 10 nM estradiol
(E2, white bars). Data represent means ± SD.
(B) PDEF and PRmRNA levels were determined by real-time PCR after MCF7 cells were treated with increasing E2 doses for 6 hr (left), 12 hr (middle), and 24 hr
(right). mRNA levels are presented as means ± SD and normalized to the housekeeping gene GAPDH.
(legend continued on next page)
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Pol2 ChIP Figure 4. GATA3 Prevents PDEF Induction
by ER
(A) GATA3 (upper) and PDEF (lower) mRNA levels
were determined by RT-qPCR after MCF7 cells
were transfected with a NS or GATA3-targeting
(KD, KnockDown) siRNAs and challenged with
10 nM estradiol (E2). Data represent means ± SD.
(B) Western blot lysates from MCF7 cells trans-
fected with NS or GATA3-targeting (KD) siRNAs,
and challenged with 10 nM estradiol.
(C) Direct RNA polymerase II (Pol2), ER, p300,
acetylated histone H3K18, and H4K12 ChIPs fol-
lowed by real-time PCR after MCF7 cells were
transfected with NS or GATA3-targeting (KD)
siRNAs, and challenged with 10 nM E2. Data
represent means ± SD. Enh., enhancer.
See also Figure S3.
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down conditions, specifically at enhancer 1. Consistent with
the histone acetyltransferase activity of p300 (McManus and
Hendzel, 2003), we found higher levels of the active histone
marks acetylated-H3K18 and -H4K12 at PDEF enhancer
1. Collectively, these data demonstrate that the loss of GATA3
allows for ER-mediated PDEF induction.
To evaluate the repressive effect of GATA3 on PDEF expres-
sion in other cell lines, we examined the mRNA levels of these
transcription factors in a subset of ER+ breast cancer cell lines
(Neve et al., 2006). Clustering analysis revealed a clear distinc-
tion between [GATA3]high [PDEF, FOXA1]low and [GATA3]low
[PDEF, FOXA1]high cell lines (Figure 5A). Pairwise correlation(C) Direct RNA polymerase II (Pol2) ChIP followed by qPCR after treatment of MCF7 cells with vehicle or 10 nM
and PR promoter (right). Data represent means ± SD.
(D) PDEF, ESR1, FOXA1, and GATA3 mRNA and protein levels were determined by RT-qPCR (left panels) o
transfected with a NS or two independent siRNAs targeting ESR1/FOXA1/GATA3 (KD, KnockDown). Data re
(E) Direct FOXA1 (upper) and GATA3 (lower ) ChIPs followed by qPCR after treatment of MCF7 cells with veh
Data represent means ± SD.
See also Figure S2.
Cancer Cell 23, 753–7analysis showed a statistically significant
inverse correlation between PDEF and
GATA3. Conversely, PDEF and FOXA1
levels were positively correlated, further
confirming the positive regulation of
PDEF expression by FOXA1. Validation
of the negative correlation between
PDEF and GATA3 expression was also
performed in four ER+ breast cancer cell
lines (Figure 5B).
PDEF Is Required for the Growth of
ER+ Breast Cancers
To investigate the role of PDEF in breast
cancer progression, we first analyzed
gene expression profiling and clinical
outcome data from published studies for
correlations between PDEF/GATA3 ex-
pression levels and overall survival (Fig-
ure 5C). Due to the strong association
between PDEF and ER expression, onlyER+ breast tumors were included in this analysis. Patients were
divided into two equal groups, high and low, based on the
median PDEF expression level. Kaplan-Meier survival analyses
in three independent data sets demonstrated that high PDEF
expression is associated with worse overall survival for patients
with ER+ breast cancer. We found that PDEF is a significant pre-
dictor of survival when treated as a continuous variable in Cox
regression models (Chin p = 0.0102, Ivshina p = 3.74 3 103,
Desmedt p = 0.0476), consistent with a previous report (Sood
et al., 2009). In contrast, GATA3 is not a significant predictor of
survival in the ER+ breast samples in these three studies when
tumors are classified based on the median GATA3 expression
or when GATA3 expression is treated as a continuous variableE2 using primers flanking the PDEF promoter (left)
r western blot (right panels) after MCF7 cells were
present means ± SD.
icle or 10 nM E2. Enh., enhancer; Prom., promoter.
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Figure 5. PDEF andGATA3Are Inversely Correlated in ER+ Luminal TumorCell Lines, and Their Expression Levels Are of Prognostic Value for
ER+ Breast Carcinoma Patient Survival
(A) Heatmap displaying GATA3, PDEF, and FOXA1 mRNA levels in eight ER+ breast cancer cell lines (Neve et al., 2006) with pairwise correlation analysis.
Scale: +1, perfect positive correlation; 0, no correlation; 1: perfect inverse correlation.
(B) GATA3 (upper) and PDEF (lower) mRNA levels were determined by real-time PCR in four ER+ breast cancer cell lines. Data represent means ± SD.
(C) Kaplan-Meier survival analysis of patients with ER+ breast carcinoma (Chin et al., 2006; Ivshina et al., 2006; Desmedt et al., 2007). Patients were stratified on
the median value for each marker. The log-rank test p values are shown.
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PDEF Is a Lineage-Specific Cancer Gene(data not shown). Interestingly, further stratification of patient
groups based on inverse GATA3/PDEF expression improves
the predictive capability of PDEF (Figure 5C). The significant
correlation between high PDEF expression and poor overall
survival strongly supports a potential role for PDEF in ER+ breast
tumorigenesis.
To assess this hypothesis, we next investigated the biologic
effects of PDEF knockdown on luminal breast cancer cell
growth. PDEF downregulation by transient transfection with
two independent siRNAs (Figure 6A) triggered a growth defect
in MCF7 cells subjected to hormone starvation prior to E2 stim-
ulation (Figure 6B). This growth defect was rescued by the
expression of a mutant PDEF protein harboring a silent mutation
preventing siRNA-mediated downregulation (Figures S4A and
S4B). Stable PDEF knockdown by transduction of MCF7 cells760 Cancer Cell 23, 753–767, June 10, 2013 ª2013 Elsevier Inc.with lentiviral PDEF-targeting shRNAs also induced a growth
defect in conditions of hormone depletion followed by E2 stimu-
lation (Figures S4C and S4D).
Flow cytometry analysis did not reveal any obvious cell-cycle
progression defect in PDEF knockdown cells subjected to hor-
mone starvation and E2 induction. However, PDEF knockdown
followed by treatment with nocodazole prevented a significant
proportion of cells from entering mitotic arrest, suggesting that
PDEF silencing does induce a subtle G0/G1 arrest (Figure S4E).
In addition, PDEF knockdown cells subjected to hormone deple-
tion displayed decreased viability with a statistically significant
increase in apoptotic cells (Figure 6C). Based on this finding,
we examined the effect of the ER antagonists tamoxifen and
fulvestrant in cells expressing PDEF siRNA (Figure 6D).
Increasing doses of anti-estrogens resulted in more pronounced
Cancer Cell
PDEF Is a Lineage-Specific Cancer Genecytotoxicity in PDEF knockdown conditions. In addition,
caspase 8 activity was also increased in MCF7 cells expressing
PDEF-targeting shRNAs and subjected to hormone depletion or
fulvestrant treatment (Figure S4F), further confirming a role for
PDEF in mediating luminal tumor cell survival in response to
hormone-related stress.
We also examined the effect of PDEF loss on luminal tumor cell
survival in anchorage-independent conditions. Soft agar colony
formation was markedly decreased in MCF7 cells expressing
PDEF shRNA, suggesting that this ETS factor is essential for
the transformation of luminal tumor cells (Figure 6E). Consistent
with this notion, PDEF downregulation in three other luminal
cancer cell lines, T47D, BT474, and SKBR3 (Figure S4G),
resulted in similar decreases in cell growth (Figures S4H–S4J)
and significantly impaired colony formation in soft agar assays
(Figures S4K and S4L). As a control, we demonstrated that re-
introduction of PDEF in the basal tumor cell line SUM159, which
lacks endogenous PDEF expression, inhibited anchorage-
independent growth and survival (Figure S4M), confirming the
reported role of PDEF as a tumor suppressor in basal-like breast
cancer (Feldman et al., 2003; Turner et al., 2007). To further test
the role of PDEF in luminal tumor formation, NS control or PDEF
knockdown MCF7 cells were injected in the inguinal mammary
fat pads of NOD-SCID mice that had previously been implanted
with an estrogen pellet (Figure 6F). In line with the observed
in vitro growth defect, PDEF downregulation reduced tumor
growth, with a 40% decrease in final tumor weight compared
to tumors formed by control MCF7 cells. Interestingly, histolog-
ical sections of PDEF knockdown tumors displayed a frag-
mented appearance and decreased cellularity, in contrast to
the suppressive role of PDEF in basal SUM159 cells, because
expression of PDEF in these cells diminished tumor formation
in vivo (Figure S4N). Western blot analysis of lysates from
PDEF knockdown tumors revealed increased detection of
cleaved caspase 8, whereas the proliferation marker PCNA
was not differentially expressed (Figure 6G), indicating that the
reduced tumor size of PDEF knockdown xenograft tumors is
predominantly due to increased apoptosis rather than a prolifer-
ation defect. TUNEL cell death detection in tumor sections also
clearly showed increased cell death in PDEF knockdown tumors
(Figure 6H). Collectively, these data support a critical prosurvival
role of PDEF in ER+ breast cancer cells. Conversely, we
confirmed a tumor-suppressive function for GATA3 (Asselin-
Labat et al., 2007; Kouros-Mehr et al., 2008), because GATA3
silencing promoted soft agar colony formation in MCF7 cells
(Figures S4O and S4P).
PDEF Is Involved in Endocrine Resistance
To better understand the mechanisms underlying acquired
endocrine resistance, in vitro models of hormone-independent
growth were previously developed through long-term culture of
MCF7 cells in media devoid of any estrogens or in the presence
of tamoxifen (Ariazi et al., 2011). We hypothesized that PDEF
might play a functional role in this hormone-refractory phenotype
based on our finding that PDEF downregulation sensitizedMCF7
cells to hormone depletion and anti-estrogens. To evaluate this
hypothesis, we analyzed two long-term estrogen-deprived
clones (MCF7 2A and 5C) (Ariazi et al., 2011) and tamoxifen-
resistant cells (TAM-R) isolated from parental MCF7 cells.PDEF mRNA levels were higher in estrogen-deprived 2A and
5C cells relative to the parental controls (WS8), whereas the
levels of GATA3 mRNA were lower (Figure 7A). The inverse cor-
relation between PDEF and GATA3 was confirmed in this model
at the protein level (Figure 7B). Similarly, TAM-R cells also dis-
played higher PDEF levels, concomitant with undetectable levels
of GATA3 mRNA and protein (Figures 7A and 7B). To determine
whether the higher PDEF expression observed in these models
was functionally relevant, we assessed the survival of MCF7
5C cells after PDEF downregulation. PDEF knockdown induced
increased cell death and a reduction in soft agar colony forma-
tion, suggesting that hormone-refractory cells are partially
dependent on PDEF for survival (Figure 7C). In addition, PDEF
downregulation in MCF7 TAM-R cells triggered a dramatic
decrease in soft agar colony formation (Figure 7D). Interestingly,
tamoxifen significantly increased colony numbers of TAM-R cells
transduced with a NS shRNA (compare white bars), indicating
that tamoxifen functions in TAM-R cells as an agonist to promote
anchorage-independent cell growth. In fact, PDEF silencing
resulted in a greater fold-reduction in colony formation in the
presence of tamoxifen compared to the vehicle condition. These
results support the conclusion that PDEF plays an important role
in endocrine resistance.
PDEF Gene Expression Signature Reflects a Prosurvival
Role and Identifies Cell Death Receptor FAS as an
Important Target
Microarray gene expression analysis was performed in MCF7
cells transduced with NS or PDEF-targeting shRNAs after sub-
jection to hormone depletion for 48 hr. Analyses of differentially
expressed genes combined with gene ontology revealed a
downregulation of cell cycle-related genes and an upregulation
of apoptosis-related genes in PDEF knockdown cells (Figure 8A).
A complete list of PDEF-regulated genes from this microarray
analysis is shown in Table S2. These target genes constitute
potential effectors of the prosurvival role of PDEF.
We next examined whether PDEF-regulated genes have
prognostic value for survival of patients with ER+ breast carci-
noma (Figure 8B). A semisupervised principal component
method was implemented using the PDEF-regulated genes in
MCF7 cells; we did not include the PDEF probe because it
is prognostic as a single predictor. Using this approach, a
130-probe PDEF signature that is able to predict patient
outcome in the Ivshina data set was identified (Figure 8B; Table
S3). Importantly, this signature is also significant when applied to
independent cohorts of ER+ tumors (Figure S5A). Because
increased expression of cell cycle genes is a hallmark of cancer,
it was necessary to define whether cell cycle genes solely
contribute to the prognostic value of the PDEF signature.
Survival analysis using a PDEF signature where cell cycle-asso-
ciated genes were eliminated revealed that non-cell cycle PDEF-
regulated genes are prognostic (Figure S5B, left panel). A PDEF
signature restricted to genes implicated in response to stress
and apoptosis is also prognostic (Figure S5B, right panel).
To further define the clinical relevance of PDEF target genes,
we analyzed the overlap between the PDEF signature and exist-
ing breast carcinoma gene expression data sets. A large pro-
portion of genes upregulated in PDEF knockdown MCF7 cells
were significantly downregulated in tumors versus normalCancer Cell 23, 753–767, June 10, 2013 ª2013 Elsevier Inc. 761
Figure 6. PDEF Knockdown Sensitizes MCF7 Cells to Hormone-Related Stress and Decreases Their Tumorigenic Properties
(A)PDEFmRNA levels were determined by real-time PCR inMCF7 cells transfected with NS or two independent PDEF-targeting (PDEF KD, KnockDown) siRNAs,
and then grown for 3 days in hormone-depleted medium with 10 nM E2. Data represent means ± SD.
(B) Growth curves of MCF7 cells transfected with NS or PDEF-targeting (KD) siRNAs in hormone-depleted medium with 10 nM E2. Data represent means ± SD.
(C) AnnexinV/Propidium Iodide cell viability measurement of MCF7 cells transfected with NS or PDEF-targeting (KD) siRNAs, then grown for 24 hr in hormone-
depleted medium. Data represent means ± SD.
(D) Measurement of cytotoxicity after transfection of MCF7 cells with NS or PDEF-targeting (KD) siRNAs, followed by treatment for 48 hr with increasing doses of
tamoxifen (left) or fulvestrant (right). Data represent means ± SD.
(E) Soft agar colony formation assay of MCF7 cells infected with NS or PDEF-targeting (KD) shRNAs. The average fold change ± SEM in colony number compared
to control NS cells across three independent experiments is shown (*p < 0.02, ***p < 0.0001).
(F) Measurement of MCF7 xenograft tumor weight. Mammary fat pads of NOD/SCID mice were injected with NS or PDEF-targeting shRNA (KD
#1 and #2) MCF7 cells. Estradiol release pellets were implanted subcutaneously 2–3 days prior to surgery. Tumors were harvested and weighed
after 8 weeks of growth. Data represent mean ± SEM, *p < 0.04. Tumor sections were analyzed with hematoxylin and eosin staining. Scale bars represent
50 mM.
(G) Western blots of MCF7 xenograft tumor lysates. Tumors expressing either NS or PDEF-targeting (KD) shRNAs were analyzed.
(legend continued on next page)
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Figure 7. PDEF Expression Is Increased in
Long-Term Estrogen-Deprived Cells and
Tamoxifen-Resistant Cells Derived from
MCF7 Cells
(A and B) PDEF and GATA3 mRNA and protein
levels were determined by real-time PCR (A) or
western blot (B) in parental MCF7 cells (WS8),
clones 2A and 5C (upper panels), and tamoxifen-
resistant (TAM-R) cells (lower panels). mRNA
levels are presented as means ± SD and normal-
ized to the housekeeping gene GAPDH.
(C) Left: PDEF mRNA levels were determined in
MCF7 5C cells by real-time PCR after transfection
of NS or PDEF-targeting (PDEF KD, KnockDown)
siRNAs. Middle: measurement of MCF7 5C cell
mortality (**p < 0.005, data represent mean ±SD).
Right: soft agar colony formation assay of MCF7
5C cells infected with NS or PDEF-targeting (KD)
shRNAs. Data represent the average fold change ±
SEM in colony number compared to control NS
cells, *p < 0.02.
(D) Left: PDEF mRNA levels were determined in
MCF7 TAM-R cells by real-time PCR 7 days after
transduction of NS or PDEF-targeting (KD)
shRNAs in the presence of 107 M tamoxifen or
vehicle (EtOH). Right: soft agar colony formation
assay of MCF7 TAM-R cells infected with NS
control shRNA or PDEF-targeting shRNA (KD)
in the presence of 107 M tamoxifen or vehicle
(EtOH) (***p < 0.001, *p < 0.05). Data represent
means ± SD.
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down MCF7 cells were overexpressed in tumors compared to
normal samples (Figure S5C). These findings demonstrate that
PDEF knockdown triggers a gene expression program that
switches cells toward a less tumorigenic phenotype.
In addition, we further analyzed these microarray results to
identify potential mediators of the pro-apoptotic phenotype
induced by PDEF loss. The cell death receptor FASwas selected
as a candidate effector because FASmRNA was overexpressed
in MCF7 cells with PDEF knockdown under hormone-depleted
conditions (Figures 8C and 8D), suggesting that PDEF acts as
a repressor of FAS expression. Furthermore, analysis of a previ-
ously published PDEF cistrome established in VCaP prostate
cancer cells (Wei et al., 2010) revealed the presence of a PDEF(H) Tumor sections were subjected to TUNEL cell death staining (red). Nuclei were stained with DAPI (blue). T
(NS, PDEF KD#1 and #2) and five fields were photographed for each section. Representative images for each
The ratio of TUNEL signal to the total number of nuclei is shown in the histogram. Data represent means ± S
See also Figure S4.
Cancer Cell 23, 753–7binding region located upstream of the
FAS gene locus. Direct PDEF ChIP in
MCF7 cells confirmed PDEF recruitment
to this binding region (Figure 8E). This
result indicates that PDEF directly re-
presses FAS expression and that this
inhibition may promote the survival of
MCF7 cells in hormone-depleted media.
Interestingly, an inverse correlation
between FAS and PDEF mRNA levelswas observed in multiple ER+ breast carcinoma data sets (Fig-
ure S5D), thus confirming that PDEF-mediated repression of
FAS expression is also relevant clinically.
To determine if FAS plays a functional role in the pro-
apoptotic phenotype, we treated PDEF knockdown MCF7 cells
with an anti-FAS Ligand (FasL) neutralizing antibody under
hormone-depleted conditions (Figure 8F). FasL neutralizing
antibody was sufficient to partially rescue the apoptotic pheno-
type in PDEF knockdown cells as compared to a negative
control NS antibody. Moreover, FAS mRNA and protein
expression were enhanced in both MCF7 2A and 5C clones
upon PDEF downregulation (Figures 8G and 8H). Based on
these findings, we hypothesize that increased PDEF levels pro-
mote the acquired endocrine resistance of estrogen-deprivedhree different tumors were stained for each shRNA
tumor type are shown. Scale bars represent 20 mM.
D (***p < 0.001).
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Figure 8. PDEF Promotes a Pro-Survival Gene Expression Program in Hormone-Depleted Conditions and Represses Pro-Apoptotic Death
Domain FAS Receptor Expression
(A) Heatmap of a selection of differentially expressed genes generated from microarray analysis of MCF7 cells infected with NS or PDEF-targeting (PDEF KD,
KnockDown) shRNAs, then subjected to hormone depletion for 48 hr. These expression changes were statistically significant.
(B) Kaplan-Meier survival analysis of the relationship between survival time and the PDEF signature. The PDEF signature was trained and tested on the Ivshina
data set (Ivshina et al., 2006). The log-rank p-value is an indicator of significant differences in patient outcomewhen patients are dichotomized at themedian of the
predictor. The Cox p value treats the predictor as a continuous variable.
(C and D) PDEF and FASmRNA and protein levels were determined by real-time PCR (C) or western blot (D) inMCF7 cells infectedwith NS or PDEF-targeting (KD)
shRNAs, and grown for 48 hr (C) or 72 hr (D) in hormone-depleted medium. mRNA levels are presented as means ± SD and normalized to the housekeeping gene
GAPDH.
(E) Upper: schematic diagram of the PDEF binding region (indicated by arrow) upstream of the FAS gene locus as defined by PDEF ChIP sequencing in VCaP cells
(Wei et al., 2010). Lower: direct PDEF ChIP followed by qPCR after culture of MCF7 cells in hormone-depleted medium for 48 hr. Data represent means ± SD.
(legend continued on next page)
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PDEF Is a Lineage-Specific Cancer Genecells by inhibiting the expression of pro-apoptotic genes
including FAS.
DISCUSSION
In this study, we demonstrated that PDEF is a downstream
target of the ER/FOXA1/GATA3 network. In addition to its
critical function as a lineage-specific regulator of ER+ breast
cancer cell survival, PDEF also induces luminal differentiation
of nontransformed basal epithelial cells (summarized in Figures
8I–8K).
Gene expression analyses revealed distinct PDEF signatures
in two different contexts. PDEF overexpression in nontrans-
formed MCF-10A mammary basal epithelial cells induced a
striking luminal differentiation program, whereas PDEF knock-
down in transformed luminal MCF7 cells subjected to hormone
depletion induced a growth arrest and cell death program. The
lack of significant overlap in these signatures suggests distinct
roles for PDEF in the context of normal morphogenesis and
tumorigenesis. Defining PDEF binding sites in the genome in
these two contexts may reveal differential sets of direct target
genes and cooperating factors. However, the role of PDEF in
promoting survival is likely more important than its role in regu-
lating differentiation in transformed cells because preliminary
data suggest that PDEF knockdown induces changes in a subset
of differentiation markers in luminal breast cancer cells, but does
not appear to result in the generation of bipotent cells as
observed in nontransformed COMMA-1D cells.
The dichotomous functions of PDEF in the context of normal
and tumor cells distinguish it from other prodifferentiation factors
that function as tumor suppressors. For example, GATA3 is
required for luminal cell differentiation (Asselin-Labat et al.,
2007); however, GATA3 downregulation enhances invasive
activity and tumor cell dissemination to the lung, whereas
GATA3 overexpression suppresses metastasis (Kouros-Mehr
et al., 2008). In addition, GATA3 is mutated in 17.7% of ER+
breast carcinoma samples (Stephens et al., 2012). Interestingly,
GATA3 silencing increased ER-binding intensity in a high
proportion of recruiting regions (Theodorou et al., 2013). We hy-
pothesize that PDEF could be an important target of the tumor-
suppressive action of GATA3. The analysis of estrogen-deprived
or tamoxifen-resistant cells provides supportive evidence for an
inverse correlation between PDEF andGATA3, whichmay repre-
sent a marker of hormone-refractory breast cancers.
Studies of PDEF function in different cancers, including pros-
tate and ovarian tumors, suggests a context-dependent role in
tumorigenesis (Johnson et al., 2010; Sood et al., 2007; Ghader-
sohi et al., 2008; Rodabaugh et al., 2007). In breast cancer, PDEF
cooperates with the oncogenes ERBB2 and CSF1R to promote
cell motility, invasion, and anchorage-independent growth of
mammary epithelial cells (Gunawardane et al., 2005). In contrast,(F) Measurement of caspase 8 activity in MCF7 cells transfected with NS or PD
presence of a negative control antibody or anti-Fas Ligand antibody (FasL, 5 ng
(G and H) PDEF and FASmRNA and protein levels were determined by real-time P
targeting (KD) shRNAs. mRNA levels are presented as means ± SD and normaliz
(I) PDEF belongs to a network of ER-associated factors and is positively regulate
(J) Mechanism of GATA3-mediated repression of PDEF.
(K) Physiologic and pathologic functions of PDEF.
See also Figure S5 and Tables S2 and S3.other studies showed that ectopic expression of PDEF in highly
malignant, ER, basal-like breast tumor cell lines (Feldman et al.,
2003; Turner et al., 2007) resulted in reduced proliferation,
motility, and invasiveness, suggestive of a tumor suppressor
role. However, the relevance of ectopic expression in tumor
cell lineages in which PDEF is not normally expressed is difficult
to interpret. Exogenous expression of ER in ER cells led to
similar paradoxical results, in which ER appeared to function
as a tumor suppressor (Levenson and Jordan, 1994). Luminal
epithelial-specific transcription factors, such as ER and PDEF,
may reduce the mesenchymal properties of these cell lines,
rendering them less invasive andmigratory. Thus, loss of expres-
sion studies in ER+ cells represents a more appropriate context
to examine the role of PDEF in tumorigenesis. Our data support a
role for PDEF in breast cancer progression, at least in part by
maintaining a proliferative state and enabling a prosurvival
gene expression program.
Our results identify the FAS receptor, a member of the tumor
necrosis family involved in the extrinsic apoptosis pathway
(Peter and Krammer, 2003), as a direct PDEF transcriptional
target. Nontransformed mammary epithelial cell lines express
high levels of FAS, and its expression is decreased in several
breast cancer cell lines (Keane et al., 1996). In addition, dis-
ease-free survival was significantly longer in patients with
FAS-positive breast tumors compared to those with FAS-
negative tumors (Mottolese et al., 2000). PDEF represses FAS
gene expression, specifically under stress conditions such as
hormone depletion. Several other ETS factors also display tran-
scriptional-repressive activities, including Net, Yan, ERF, and
Tel (Mavrothalassitis and Ghysdael, 2000). The mechanism of
PDEF-mediated repression is not yet elucidated, and the iden-
tification of potential coregulators will provide new insights into
its transcriptional activity.
Taken together, this study identifies PDEF not only as an
essential factor within the ER-associated transcriptional
network, but also as a potential therapeutic target for patients
with ER+ breast carcinoma.
EXPERIMENTAL PROCEDURES
Reagents, Cells, and Tissue Culture Conditions
The antibodies, siRNAs, primers, and cells and tissue culture conditions are
listed in the Supplemental Experimental Procedures. Reduction mastectomy
tissues were collected from patients who have provided informed consent
under the DFCI IRB approved protocol 93-085. See the Supplemental
Experimental Procedures for more details.
Gene Expression Microarray Analysis
Total RNA was isolated either from MCF-10A cells expressing pBabe/pBabe-
PDEF or from MCF7 expressing NS/PDEF-targeting shRNA and subjected to
reverse transcription, labeling, and hybridization to hgu133plus2 gene chip
arrays (Affymetrix). See the Supplemental Experimental Procedures for more
details.EF-targeting (KD) siRNAs, then subjected to hormone depletion (48 hr) in the
/ml). Data represent means ± SD.
CR (G) or western blot (H) in MCF7 2A and 5C clones infected with NS or PDEF-
ed to the housekeeping gene GAPDH.
d by ER and FOXA1, whereas GATA3 acts as a repressor of PDEF expression.
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PDEF Is a Lineage-Specific Cancer GeneLentiviral Infection and siRNA Transfection
Lentivirus was produced in 293T cells and retrovirus in 293GPG cells. For
luminal progenitor cells, PDEF-targeting lentiviral particles were obtained
fromSanta Cruz Biotechnology (sc-45845-V). For PDEF overexpression, either
the retroviral pBabe or lentiviral pBob vectors containing human or murine
PDEF cDNA were used. See the Supplemental Experimental Procedures for
more details.
Chromatin Immunoprecipitation
ChIP was performed as previously described (Carroll et al., 2006). See Supple-
mental Experimental Procedures for more details.
Growth Curves and Cytotoxicity Assay
Growth of MCF7 cells and cytotoxicity of tamoxifen and fulvestrant were
measured using the cell proliferation WST-1 assay (Roche). See the Supple-
mental Experimental Procedures for more details.
Annexin V Analysis of Apoptosis and Caspase 8 Activity Assay
The Vybrant annexin V Kit #3 and the ApoTarget Caspase 8 colorimetric assay
(Invitrogen) were used. See the Supplemental Experimental Procedures for
more details.
Immunofluorescence
MCF-10A cells were stained with antibodies against cytokeratin-8 (Covance
HK-8) and keratin-14 (Covance AF64). COMMA-1D colony assays were
stained with antibodies against murine cytokeratin-8 (DSHB, University of
Iowa; TROMA-I) and keratin-14 (Covance AF641). See the Supplemental
Experimental Procedures for more details.
Flow Cytometry Analyses
MCF-10A and HMEC cells were trypsinized and resuspended in flow buffer
(PBS containing 1% BSA, 2 mM EDTA, and 5% FBS) for 10 min. Cells were
stained for 30 min with antibodies for PE-conjugated EpCAM and APC-conju-
gated CD10 (both eBioscience). Analysis was performed on a FACS Calibur
machine (BD).
Soft Agar Assays
Six-well plates were coated with an underlay of 0.5% agarose (Sigma, type VII
low melting). Cells were then plated in 0.35% agarose. Colonies were allowed
to form for approximately 2 weeks. See the Supplemental Experimental
Procedures for more details.
Fat Pad Tumor Assays
All animal studies were performed with the approval of the IACUC of Harvard
Medical School. Eight-week-old female NOD/SCID mice were implanted with
estrogen pellets (Innovative Research of America; 0.72 mg, 60 day release)
prior to injection to support tumor growth; 23 106MCF7 cells (expressing con-
trol or PDEF-targeting shRNAs, resuspended inMatrigel) were injected into the
number 4 fat pad. Tumors were harvested after 8 weeks of growth. See the
Supplemental Experimental Procedures for more details.
Survival Analysis
Breast tumor data sets were downloaded from http://www.ncbi.nlm.nih.gov/
geo (Ivhsina; GSE4922), (Desmedt; GSE7390) and http://www.ebi.ac.uk/
arrayexpress (Chin; E-TABM-158). See the Supplemental Experimental
Procedures for more details.
ACCESSION NUMBERS
The GEO accession number for the raw and processed microarray data pre-
sented in this paper is GSE40987.
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